Evidence map›Paper›PMID 31042470›Full record

ArticleCell reports2019

Comprehensive Profiling of HIV Antibody Evolution.

Susan H Eshleman, Oliver Laeyendecker, Kai Kammers, Athena Chen, Mariya V Sivay, Sanjay Kottapalli, Brandon M Sie, Tiezheng Yuan, Daniel R Monaco, Divya Mohan and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Proviruses in CD4Science translational medicine · 2025
    Article
  8. Article
  9. Review
  10. PhIP-Seq: methods, applications and challenges.Frontiers in bioinformatics · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Clinical Application Evaluation of ElecsysFrontiers in cellular and infection microbiology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Susan H EshlemanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: seshlem@jhmi.edu.
Oliver LaeyendeckerLaboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kai KammersDivision of Biostatistics and Bioinformatics, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Athena ChenDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Mariya V SivayDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sanjay KottapalliDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Brandon M SieDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tiezheng YuanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel R MonacoDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Divya MohanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel WansleyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tomasz KulaDivision of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Department of Genetics, Harvard University Medical School, Boston, MA 02115, USA.
Charles MorrisonFHI 360, Clinical and Epidemiologic Sciences, Durham, NC, USA.
Stephen J ElledgeDivision of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Department of Genetics, Harvard University Medical School, Boston, MA 02115, USA.
Ron BrookmeyerDepartment of Biostatistics, University of California at Los Angeles, Los Angeles, CA, USA.
Ingo RuczinskiDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
H Benjamin LarmanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: hlarman1@jhmi.edu.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Nina Thawata Harawa · 1997 to 2026
$53.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Laboratory and Statistical Development of Cross-Sectional HIV Incidence AssaysR01AI095068 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2011 to 2021
$6.6M
Development of Highly Multiplex Antigen Specificity AssaysU24AI118633 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ELLEDGE, STEPHEN J, LARMAN, HARRY BENJAMIN · 2015 to 2020
$2.4M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA006973NIAID NIH HHS R01 AI095068NIAID NIH HHS U24 AI118633NIAID NIH HHS UM1 AI068613NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

This study evaluates HIV antibody responses and their evolution during the course of HIV infection. A phage display system is used to characterize antibody binding to >3,300 HIV peptides in 57 adults with early- to late-stage infection. We find that the number of unique epitopes targeted ("antibody breadth") increases early in infection and then stabilizes or declines. A decline in antibody breadth 9 months to 2 years after infection is associated with subsequent antiretroviral treatment (ART) initiation, and a faster decline in antibody breadth is associated with a shorter time to ART initiation. We identify 266 peptides with increasing antibody reactivity over time and 43 peptides with decreasing reactivity over time. These data are used to design a prototype four-peptide "serosignature" to predict duration of HIV infection. We also demonstrate that epitope engineering can be used to optimize peptide binding properties for applications such as cross-sectional HIV incidence estimation.

Indexed as

Antibody SpecificityAdultAnti-HIV AgentsCD4-Positive T-LymphocytesEpitopesFemaleHIV AntibodiesHIV AntigensHIV SeropositivityHumansAnti-HIV AgentsEpitopesHIV AntibodiesHIV Antigensantibody biomarkerantibody profilingantibody response to HIVHIV incidenceimmunodominant HIV epitopesserosignature

Identifiers

PMID31042470
PMCPMC6519133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.